Wang Wenjie, Tonelli Marcello, Hemmelgarn Brenda, Gao Song, Johnson Jeffrey A, Taub Ken, Manns Braden
Department of Medicine, Division of Nephrology, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
Am J Kidney Dis. 2008 May;51(5):796-803. doi: 10.1053/j.ajkd.2007.12.031. Epub 2008 Apr 2.
Using standard hemodialysis regimens, overweight patients often do not reach Kidney Disease Outcomes Quality Initiatives (KDOQI) Kt/V targets, and this has been associated with lower health-related quality of life (HRQL). Whether increasing dialysis adequacy in large patients not achieving KDOQI targets improves HRQL is unknown.
Randomized blinded crossover study.
SETTING & PARTICIPANTS: Overweight (>80 kg) underdialyzed patients from 6 dialysis units in 2 Canadian dialysis programs.
Six-week treatment periods with a standard dialysis regimen (4 hours 3 times weekly) and 3 augmented regimens: 4.5 hours of hemodialysis, 4 hours of hemodialysis with increased dialysate flow, and 4 hours of hemodialysis with 2 dialyzers in parallel.
OUTCOMES & MEASUREMENTS: The End-Stage Renal Disease Symptom domain of the Kidney Disease Quality-of-Life Short-Form questionnaire (primary outcome) and the Health Utilities Index Mark 2 (secondary outcome).
We enrolled 18 patients (mean weight, 109.7 +/- 16.2 [SD] kg); 12 completed all 4 regimens. Mean Kt/Vs during the study were 1.27 (95% confidence interval [CI], 1.19 to 1.35), 1.41 (95% CI, 1.32 to 1.50), 1.31 (95% CI, 1.22 to 1.39), and 1.41 (95% CI, 1.33 to 1.49) for patients receiving standard dialysis, 4.5 hours of hemodialysis, hemodialysis with increased dialysate flow, and hemodialysis with 2 dialyzers, respectively. Kidney Disease Quality-of-Life End-Stage Renal Disease Symptom domain and Health Utilities Index Mark 2 scores were 75.9 (95% CI, 70.7 to 81.2) and 0.69 (95% CI, 0.56 to 0.81) for patients receiving standard dialysis, respectively. These did not differ when patients received the 3 augmented dialysis regimens (P = 0.2 and P = 0.5, respectively).
Small sample size and inability to fully blind patients to the treatment they were receiving.
Improving hemodialysis adequacy for large underdialyzed patients did not lead to improved HRQL. Our findings suggest that augmentation of the dialysis regimen is not required for these patients in the absence of overt uremic symptoms.
采用标准血液透析方案时,超重患者往往无法达到肾脏病预后质量倡议(KDOQI)的Kt/V目标,而这与较低的健康相关生活质量(HRQL)相关。对于未达到KDOQI目标的超重患者,增加透析充分性是否能改善HRQL尚不清楚。
随机双盲交叉研究。
来自加拿大2个透析项目中6个透析单元的超重(>80 kg)透析不充分患者。
为期6周的治疗期,采用标准透析方案(每周3次,每次4小时)和3种强化方案:4.5小时血液透析、增加透析液流量的4小时血液透析以及并行使用2个透析器的4小时血液透析。
肾脏病生活质量简表问卷的终末期肾病症状领域(主要结果)和健康效用指数Mark 2(次要结果)。
我们纳入了18例患者(平均体重,109.7±16.2[标准差]kg);12例完成了所有4种方案。在研究期间,接受标准透析、4.5小时血液透析、增加透析液流量的血液透析和使用2个透析器的血液透析的患者的平均Kt/V分别为1.27(95%置信区间[CI],1.19至1.35)、1.41(95%CI,1.32至1.50)、1.31(95%CI,1.22至1.39)和1.41(95%CI,1.33至1.49)。接受标准透析的患者的肾脏病生活质量终末期肾病症状领域和健康效用指数Mark 2评分分别为75.9(95%CI,70.7至81.2)和0.69(95%CI,0.56至0.81)。当患者接受3种强化透析方案时,这些评分没有差异(分别为P = 0.2和P = 0.5)。
样本量小且无法让患者完全对所接受的治疗不知情。
改善透析不充分的超重患者的血液透析充分性并未导致HRQL改善。我们的研究结果表明,在没有明显尿毒症症状的情况下,这些患者不需要强化透析方案。